Arcellx Inc (ACLX) AI Stock Analysis

• Market Cap: $4.75B
• Dividend Yield: N/A
• Average Volume (3M): 545.90K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.66
• Revenue Growth: -60.63%
• EPS Growth: -216.87%
• Country: US
• Employees: 163
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.94
• Shares Outstanding: 55,458,910
• 10 Day Avg. Volume: 586,031
• 30 Day Avg. Volume: 545,903
• PEG Ratio: -1.06
• Price to Book (P/B): 9.03
• Price to Sales (P/S): 38.06
• P/FCF Ratio: -42.39
• Enterprise Value/Market Cap: 0.70
• Enterprise Value/Revenue: 57.94
• Enterprise Value/Gross Profit: 59.64
• Enterprise Value/Ebitda: -17.62
• 1Y Price Target: $115.46
• Price Target Upside: 38.51% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 15

• Rating: 56 Neutral
• Price Target: $89.00 ▲(6.77% Upside)

Arcellx Inc's overall stock score is primarily influenced by its strong technical indicators, suggesting positive market momentum. However, significant financial challenges and a weak valuation score due to ongoing losses and lack of dividends weigh heavily on the overall score. The absence of earnings call data and corporate events means these factors do not contribute to the score.

Positive Factors

Innovative Therapy Platform

Arcellx's focus on a proprietary cell therapy platform positions it as a leader in innovative cancer treatments, offering potential for long-term growth as these therapies gain market acceptance and regulatory approval.

Strategic Partnerships

Strategic partnerships provide Arcellx with funding, distribution networks, and resources, enhancing its ability to commercialize therapies and sustain long-term growth despite current financial challenges.

Low Leverage

Low leverage indicates financial prudence, allowing Arcellx flexibility to invest in R&D and strategic initiatives without the burden of heavy debt, supporting long-term stability.

Negative Factors

Declining Revenue

Declining revenue growth highlights challenges in product commercialization and market penetration, potentially impacting long-term financial health and competitive positioning.

Negative Profitability Metrics

Ongoing losses reflected in negative profitability metrics suggest operational inefficiencies and the need for strategic improvements to achieve sustainable profitability and shareholder value.

Cash Flow Challenges

Negative cash flow indicates difficulties in funding operations and growth initiatives internally, which may necessitate external financing, impacting financial flexibility and long-term viability.

Arcellx Inc Business Overview & Revenue Model

Company Description

Arcellx Inc (ACLX) is a biotechnology company focused on developing innovative therapies for patients with cancer and other severe diseases. The company specializes in the development of its proprietary cell therapy platform, which leverages the unique properties of genetically engineered T cells to target and eliminate cancer cells. Arcellx is primarily engaged in the research, development, and commercialization of its lead product candidates, which are designed to address significant unmet medical needs in hematologic malignancies and other related conditions.

How the Company Makes Money

Arcellx generates revenue primarily through the development and commercialization of its therapeutic products. The company may earn revenue from product sales once its therapies receive regulatory approval and are launched in the market. Additionally, Arcellx can benefit from strategic partnerships and collaborations with larger pharmaceutical companies, which may include upfront payments, milestone payments, and royalties on sales. These partnerships not only provide funding for ongoing research and development but also facilitate access to broader distribution networks and resources. Furthermore, grants and funding from governmental or non-profit organizations focused on cancer research may also contribute to the company's financial resources.

Arcellx Inc Financial Statement Overview

Summary

Arcellx Inc operates in a capital-intensive biotechnology sector, with strong cash reserves and equity but faces profitability challenges. Despite signs of improvement in free cash flow, consistent negative earnings suggest ongoing financial pressure.

Income Statement

Arcellx Inc has shown fluctuating revenue with a recent decline in TTM revenue compared to the previous year. The gross profit margin remains high, but negative EBIT and net profit margins indicate ongoing losses. The company faces challenges with profitability as it continues to invest heavily in its operations.

Balance Sheet

The balance sheet reveals a strong equity position with a positive equity ratio. However, the debt-to-equity ratio is moderate, suggesting manageable leverage. The company’s cash reserves are healthy, which can support its operations despite the losses.

Cash Flow

Operating cash flow is negative, highlighting cash burn, but a significant free cash flow improvement was noted in 2023. The company's cash flow from operations to net income ratio is negative, indicating challenges in converting its operations into cash.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	56.98M	107.94M	110.32M	0.00	0.00	0.00
Gross Profit	55.36M	107.94M	110.32M	-2.22M	-1.04M	-629.00K
EBITDA	-187.38M	-99.06M	-64.14M	-184.74M	-63.93M	-31.47M
Net Income	-187.99M	-107.35M	-70.69M	-188.68M	-63.93M	-32.09M
Balance Sheet
Total Assets	619.09M	711.33M	825.13M	313.82M	128.78M	57.69M
Cash, Cash Equivalents and Short-Term Investments	453.10M	587.58M	702.02M	254.84M	104.62M	46.60M
Total Debt	52.51M	54.08M	97.63M	88.13M	100.00K	0.00
Total Liabilities	226.86M	256.54M	339.75M	108.86M	250.30M	121.41M
Stockholders Equity	392.22M	454.79M	485.38M	204.95M	111.86M	50.54M
Cash Flow
Free Cash Flow	-123.24M	-96.90M	186.15M	-101.58M	-60.02M	-29.55M
Operating Cash Flow	-118.19M	-83.47M	207.57M	-99.30M	-54.24M	-28.66M
Investing Cash Flow	80.17M	-183.04M	-154.51M	-117.67M	-79.98M	-888.00K
Financing Cash Flow	125.00K	-24.09M	279.16M	252.63M	118.45M	41.66M

Arcellx Inc Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 83.36
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ACLX, the sentiment is Neutral. The current price of 83.36 is below the 20-day moving average (MA) of 85.25, above the 50-day MA of 78.28, and above the 200-day MA of 68.82, indicating a neutral trend. The MACD of 2.16 indicates Positive momentum. The RSI at 51.90 is Neutral, neither overbought nor oversold. The STOCH value of 9.91 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for ACLX.

Arcellx Inc Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ACLX	56 Neutral	$4.75B	―	-42.75%	―	-60.63%	-216.87%
PTGX	56 Neutral	$4.57B	103.82	8.61%	―	-34.45%	-69.75%
APLS	56 Neutral	$3.58B	―	-108.49%	―	20.02%	33.45%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
BEAM	51 Neutral	$3.02B	―	-41.94%	―	-82.90%	-155.64%
IMVT	45 Neutral	$3.35B	―	-77.58%	―	―	-48.38%
MLTX	41 Neutral	$588.35M	―	-40.29%	―	―	-208.46%

Arcellx Inc Corporate Events

Arcellx, Inc. Reports Increased Losses Amid Rising R&D Costs

Arcellx, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative cell therapies for cancer and other incurable diseases, operating primarily in the biotechnology sector. In its latest earnings report for the quarter ended June 30, 2025, Arcellx reported a significant net loss of $52.8 million, compared to a $27.2 million loss in the same period last year, reflecting increased research and development expenses and general administrative costs. The company generated $7.6 million in collaboration revenue from its partnership with Kite Pharma, a decrease from the previous year. Despite the financial losses, Arcellx maintains a strong cash position with $537.6 million in cash, cash equivalents, and marketable securities, which is expected to support its operations into 2028. Looking ahead, Arcellx’s management remains focused on advancing its clinical trials and strategic collaborations, particularly with Kite Pharma, to drive future growth and innovation in its cell therapy programs.

Arcellx’s Innovative CAR-T Therapy Study for GMG: A Potential Game-Changer

Arcellx, Inc. is conducting a Phase 1 study titled A Phase 1 Study of Anitocabtagene Autoleucel for the Treatment of Subjects With Non-oncology Plasma Cell-related Diseases. The study aims to evaluate the safety, tolerability, and preliminary efficacy of anito-cel, a BCMA-directed CAR-T cell therapy, in subjects with generalized myasthenia gravis (GMG). This research is significant as it explores a novel treatment approach for GMG, potentially offering new hope for patients with this condition.